Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in Mice

Do chronic fluoxetine treatments reduced footshock-induced posttraumatic stress disorder (PTSD) symptoms, including fear and comorbid depression, in the situational reminder phase? Moreover, are the subareas of the medial prefrontal cortex (mPFC), including the cingulate cortex 1 (Cg1), prelimbic co...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying Hao Yu, Chen Yin Ou, Bai Chuang Shyu, Andrew Chih Wei Huang
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Behavioural Neurology
Online Access:http://dx.doi.org/10.1155/2020/8875087
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849467836193308672
author Ying Hao Yu
Chen Yin Ou
Bai Chuang Shyu
Andrew Chih Wei Huang
author_facet Ying Hao Yu
Chen Yin Ou
Bai Chuang Shyu
Andrew Chih Wei Huang
author_sort Ying Hao Yu
collection DOAJ
description Do chronic fluoxetine treatments reduced footshock-induced posttraumatic stress disorder (PTSD) symptoms, including fear and comorbid depression, in the situational reminder phase? Moreover, are the subareas of the medial prefrontal cortex (mPFC), including the cingulate cortex 1 (Cg1), prelimbic cortex (PrL), infralimbic cortex (IL), and basolateral amygdala (BLA), involved in the fluoxetine amelioration of PTSD symptoms? These two crucial issues were addressed in the present study. All mice were injected with chronic fluoxetine or normal saline treatments for the adaptation (14 days), footshock fear conditioning (1 day), and situational reminder (3 days) phases. After adaptation, the mice were subjected to footshock (2 mA, 10 seconds) or nonfootshock and stayed 2 min in a footshock box for 2 min for fear conditioning. Later, they were placed in the footshock box for 2 min in the situational reminder phase. In the final session of the situational reminder phase, a forced swimming test (FST) and immunohistochemical staining were conducted. The results indicated that footshock induced fear and comorbid depression. Meanwhile, chronic fluoxetine treatments reduced fear and depression behaviors. The Cg1, PrL, IL, and BLA were seemingly to increase c-Fos expression after footshock-induced PTSD symptoms in the situational reminder phase. The fluoxetine treatments reduced only the BLA’s c-Fos expression. The findings suggest that BLA contributes to the fluoxetine amelioration of PTSD symptoms; however, the mPFC, including the Cg1, PrL, and IL, did not mediate PTSD symptoms’ amelioration stemming from fluoxetine. The present data might help us to further understand the neural mechanism of fluoxetine treatments in PTSD symptoms.
format Article
id doaj-art-e6cc7a2dd55b4dfab78b72ffa8017cee
institution Kabale University
issn 0953-4180
1875-8584
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Behavioural Neurology
spelling doaj-art-e6cc7a2dd55b4dfab78b72ffa8017cee2025-08-20T03:26:03ZengWileyBehavioural Neurology0953-41801875-85842020-01-01202010.1155/2020/88750878875087Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in MiceYing Hao Yu0Chen Yin Ou1Bai Chuang Shyu2Andrew Chih Wei Huang3Department of Psychology, Fo Guang University, Yilan County 26247, TaiwanDepartment of Psychology, Fo Guang University, Yilan County 26247, TaiwanInstitute of Biomedical Sciences, Academia Sinica, Taipei, TaiwanDepartment of Psychology, Fo Guang University, Yilan County 26247, TaiwanDo chronic fluoxetine treatments reduced footshock-induced posttraumatic stress disorder (PTSD) symptoms, including fear and comorbid depression, in the situational reminder phase? Moreover, are the subareas of the medial prefrontal cortex (mPFC), including the cingulate cortex 1 (Cg1), prelimbic cortex (PrL), infralimbic cortex (IL), and basolateral amygdala (BLA), involved in the fluoxetine amelioration of PTSD symptoms? These two crucial issues were addressed in the present study. All mice were injected with chronic fluoxetine or normal saline treatments for the adaptation (14 days), footshock fear conditioning (1 day), and situational reminder (3 days) phases. After adaptation, the mice were subjected to footshock (2 mA, 10 seconds) or nonfootshock and stayed 2 min in a footshock box for 2 min for fear conditioning. Later, they were placed in the footshock box for 2 min in the situational reminder phase. In the final session of the situational reminder phase, a forced swimming test (FST) and immunohistochemical staining were conducted. The results indicated that footshock induced fear and comorbid depression. Meanwhile, chronic fluoxetine treatments reduced fear and depression behaviors. The Cg1, PrL, IL, and BLA were seemingly to increase c-Fos expression after footshock-induced PTSD symptoms in the situational reminder phase. The fluoxetine treatments reduced only the BLA’s c-Fos expression. The findings suggest that BLA contributes to the fluoxetine amelioration of PTSD symptoms; however, the mPFC, including the Cg1, PrL, and IL, did not mediate PTSD symptoms’ amelioration stemming from fluoxetine. The present data might help us to further understand the neural mechanism of fluoxetine treatments in PTSD symptoms.http://dx.doi.org/10.1155/2020/8875087
spellingShingle Ying Hao Yu
Chen Yin Ou
Bai Chuang Shyu
Andrew Chih Wei Huang
Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in Mice
Behavioural Neurology
title Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in Mice
title_full Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in Mice
title_fullStr Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in Mice
title_full_unstemmed Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in Mice
title_short Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in Mice
title_sort basolateral amygdala but not medial prefrontal cortex contributes to chronic fluoxetine treatments for ptsd symptoms in mice
url http://dx.doi.org/10.1155/2020/8875087
work_keys_str_mv AT yinghaoyu basolateralamygdalabutnotmedialprefrontalcortexcontributestochronicfluoxetinetreatmentsforptsdsymptomsinmice
AT chenyinou basolateralamygdalabutnotmedialprefrontalcortexcontributestochronicfluoxetinetreatmentsforptsdsymptomsinmice
AT baichuangshyu basolateralamygdalabutnotmedialprefrontalcortexcontributestochronicfluoxetinetreatmentsforptsdsymptomsinmice
AT andrewchihweihuang basolateralamygdalabutnotmedialprefrontalcortexcontributestochronicfluoxetinetreatmentsforptsdsymptomsinmice